C

Celldex Therapeutics

D
CLDX
USD
-0.72
(-1.7217%)
Market Closed
27,282.00
Volume
-2.5
EPS
-
Div Yield
-14.945455
P/E
2,724,420,195.60
Market Cap
Today
-1.7217%
1 Week
-1.481%
1 Month
15.840%
6 Months
1.507%
12 Months
54.395%
Year To Date
3.709%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
X
XNCR
0.36
(1.7266%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
ABBV
ABBV
0.73
(0.3784%)
USD
REGN
REGN
11.33
(0.9948%)
USD
GILD
GILD
0.015
(0.0179%)
USD
PFE
PFE
-0.09
(-0.3025%)
USD
NVS
NVS
-0.02
(-0.0172%)
USD

Title:
Celldex Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Do you need help or have a question?
Contact Us